Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells

By employing a new semi-quantitative assay system that includes co-culturin g leukemia cells with the mouse bone marrow-derived stromal cell line MS-5, we examined the suppressive effect of a selective inhibitor of ABL tyrosin e kinase, STI571, on acute lymphoblastic leukemia (ALL) cells with BCR-ABL fusion, Leukemic blast cells from eight patients with B-precursor ALL, incl uding three patients with BCR-ABL-positive ALL, were cultured on monolayers of MS-5 cells for 3 weeks with or without addition of variable amounts of STI571. In all cases, cobblestone areas (CAs) were formed, showing clear li near cell dose-dependent curves, allowing quantitative assessment of blast cell growth. The progenitor frequencies obtained by this direct CA-forming cell (CAFC) assay were equivalent to ALL progenitor frequencies assessed by the standard limiting dilution assay. The number of CAFCs ranged from 12.3 to 140.3/10(4) cells. In BCR-ABL-positive ALL patients, CA-containing cell s were examined by FISH, and all contained BCR-ABL fusion genes. STI571 inh ibited CA formation of BCR-ABL-positive ALL cells virtually 100% at 0.1-1.0 mu mol/l. None of the five BCR-ABL-negative ALL patients showed this growt h inhibition by STI571 at 0.1-1.0 mu mol/l. Our results indicate that STI57 1 selectively inhibits in vitro growth of BCR-ABL-positive ALL cells.